Enoximone

Enoximone

Clinical data
Routes of administration	Intravenous
ATC code	C01CE03 (WHO)
Legal status
Legal status	UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability	50% (oral)
Protein binding	85%
Metabolism	Hepatic oxidation
Elimination half-life	4 to 10 hours
Excretion	Renal (60 to 70%)
Identifiers
IUPAC name 4-methyl-5-(4-methylsulfanylbenzoyl)-1,3- dihydroimidazol-2-one
CAS Number	77671-31-9
PubChem CID	53708
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C12H12N2O2S
Molar mass	248.302 g/mol
3D model (JSmol)	Interactive image
SMILES CSc1ccc(cc1)C(=O)C2=C(C)NC(=O)N2

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Enoximone (INN, trade name Perfan) is an imidazole phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure.

Template:Phosphodiesterase inhibitors Template:Cardiac stimulants excluding cardiac glycosides

Template:WikiDoc Sources